 
                                            Prime Medicine to Host Virtual KOL Event to Showcase Wilson’s Disease Strategy -- Webcast event to begin at 8:00am ET on Wednesday, November 12, 2025 -- CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it will host a virtual event on Wednesday, November 12, 2025, to discuss its liver disease franchise and strategy, with a focus on Wilson’s Disease. Prime Medicine remains on track to file an investigational new d...
 
                                            Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting HOUSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced it will present at the being held October 30-31, 2025 at the MD Anderson Cancer Center Spain Foundation in Madrid, Spain. Details of the presentation are as follows: Title: L-Annamycin - Non-Cardi...
 
                                            Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin HOUSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced that the Australian Patent Office (IP Australia) has granted Patent No. 2024203598 titled, “PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE,” with claims covering certain preliposomal Annamycin lyophilizates with improved stability and high purity, w...
 
                                                                                 
                                            Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer Atlantic Health, a leading provider of health care based in New Jersey, to conduct the investigator-initiated Phase 1B/2 study Preclinical studies indicate Annamycin targets key factors in pancreatic cancer HOUSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced it is working with Atlant...
 
                                                                                 
                                                                                Dr. Hogarth completed his residency in internal medicine (1998-2001) and his fellowship in pulmonary and critical care medicine (2001-2004) before joining the University of Chicago faculty as an Assistant Professor of Medicine (2004-2014). He was later promoted to Associate Professor of Medicine (2
 
                                                                                Dr. Hogarth completed his residency in internal medicine (1998-2001) and his fellowship in pulmonary and critical care medicine (2001-2004) before joining the University of Chicago faculty as an Assistant Professor of Medicine (2004-2014). He was later promoted to Associate Professor of Medicine (2
 
                                                                                 
                                            THOR Industries Announces Regular Quarterly Dividend ELKHART, Ind., Oct. 08, 2025 (GLOBE NEWSWIRE) -- THOR Industries, Inc. (NYSE: THO) today announced that its Board of Directors approved, at its October 8, 2025, meeting, the payment of a regular quarterly cash dividend of $0.52 per share. The regular cash dividend is payable on November 6, 2025, to shareholders of record at the close of business on October 23, 2025. About THOR Industries, Inc. THOR is the sole owner of operating companies which, combined, represent the world's largest manufacturer of recreational vehicles. For more ...
 
                                                                                 
                                            Prime Medicine to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in two upcoming conferences: H.C. Wainwright Genetic Medicines Virtual Conference 2025: Fireside chat will be available to view on demand beginning Tuesday, October 14, 2025. Company management will host virtual 1x1 meetings on Wednesday, October 15, 2025.Chardan’s 9th ...
 
                                                                                 
    
 
            Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.